@LenAppleman
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!View quoted post on X
Huge congrats to Drs. @EHeath4100 & @EAntonarakis on the new Mayo/UMN #ProstateCancer SPORE grant from @NCIDCTD! 🎉 A well-deserved recognition of your leadership & a major step forward for mCRPC/APMR precision Rx research Link👉l1nq.com/mwvzc8f @PCFnews @urotodayView quoted post on X
Congrats to Dr. Mary-Ellen Taplin @DanaFarber_GU 👉 “@PCF_News Women in Science Lifetime Achievement Award at #PCFRetreat26! 🎉 a career spent following the questions & putting patients first. A well-deserved standing ovation. 👏 @PCF_Science @urotoday @DrChoueiri @DanaFarberView quoted post on X
Thrilled to see our work over years in #bladdercancer published in @Nature THANKS to patients/families consenting to our research autopsy program wanting to support others! Kudos to @HsiehLab @GavinHa #OmarMian #MingLam et al. @fredhutch @HutchPresidentView quoted post on X
nature.com/articles/s4158…
LBA1/Plenary #ASCO26: PROTEUS trial
Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC
Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage !
@DanaFarber @DanaFarber_GU @ASCO @OncoAlertView quoted post on X
